GO
| HSI1 | 24,718.10 | +468.81 | 316.44B |
| HSCEI1 | 8,374.43 | +157.35 | 90.88B |
| Back Zoom + Zoom - Block Traded | |
|
CSPC PHARMA's KN026 Combined with HB1801 for Breast Cancer Meets Primary Endpoint
2026-06-11 09:25:57 CSPC PHARMA (01093.HK) announced that the Phase III clinical study of Anbenitamab (KN026), co-developed by Shanghai JMT-BIO Technology Co., Ltd. (JMT-BIO), a subsidiary of the Company, and ALPHAMAB-B (09966.HK), in combination with the Group’s self-developed Docetaxel for Injection (Albumin-bound) (HB1801) for the first-line treatment of HER2-positive advanced breast cancer has successfully met the pre-specified primary endpoint of progression-free survival (PFS) as assessed by the Independent Data Monitoring Committee (IDMC), yielding results that are both statistically significant and clinically meaningful, with a favourable safety profile. ~ AASTOCKS Financial News Website: www.aastocks.com | |